PCSK9 and atherosclerosis: HDL-C is also considered to be a main means to preserve and possibly enhance cardiac protective function.[36,37] And multiple factors through oxidation and inflammation might lead to HDL particle dysfunction or atherosclerosis.[38,39] Most clinical trials have shown that PCSK9 inhibitors moderately increase HDL-C and apoA1 levels (usually 10%).